Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The impact of the large B-cell lymphoma tumor microenvironment on efficacy of CD19-directed CAR-T immunotherapy.

Frontiers in immunology·2026
Same author

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
Same author

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Transplantation and cellular therapy·2026
Same author

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Transplantation and cellular therapy·2026
Same author

Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma.

Transplantation and cellular therapy·2026
Same author

Impact of an Anticoagulation Management Service-Led Annual Review on Antiplatelet Use and Gastrointestinal Bleeding Prophylaxis in Ambulatory Patients on Background Direct Oral Anticoagulants.

Journal of thrombosis and thrombolysis·2026

相关实验视频

Updated: Jul 6, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

一个随机的框架来评估CAR T细胞治疗的疗效和可变性.

Chau Hoang1, Tuan Anh Phan2, Cameron J Turtle3

  • 1Department of Mathematical Sciences, New Mexico State University, Las Cruces, NM 88001, USA.

Mathematical biosciences
|January 8, 2024
PubMed
概括

这项研究使用混合方法模拟CAR T细胞疗法,考虑患者的变异性来预测治疗结果. 这些发现有助于比较不同的CAR T细胞协议,以提高患者治愈率.

关键词:
在CAR-T细胞疗法中.埃尔戈迪克分布 埃尔戈迪克分布随机模型的建模停止时间,停止时间.

更多相关视频

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

863
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

11.7K

相关实验视频

Last Updated: Jul 6, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

863
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

11.7K

科学领域:

  • 免疫学 免疫学 免疫学
  • 数学生物学 数学生物学
  • 计算生物学 计算生物学

背景情况:

  • 卡尔-T细胞疗法显示出前景,但需要针对不同患者反应进行优化.
  • 患者的变化和异质性显著影响治疗疗效.
  • 数学建模对于理解复杂的生物系统至关重要,比如癌症治疗.

研究的目的:

  • 开发和应用混合确定性-随机模型来评估CAR T细胞治疗方案.
  • 分析患者异质性和治疗结果的变化.
  • 预测不同CAR T细胞治疗策略的短期和长期疗效.

主要方法:

  • 使用伊托的随机微分方程构建了一个混合模型,将决定性和随机过程结合起来.
  • 整合了白噪声来表示患者的变异性和队列异质性的超参数.
  • 模拟的治疗方案使用过渡动态和定义的停止时间 (治愈时间,进展时间).

主要成果:

  • 随机模型确定了三个ergodic不变量,在某些条件下作为瘤生长的吸引力.
  • 随机模型的短暂动力学揭示了短期治愈的机会.
  • 治疗时间和进展时间的概率分布为三个CAR T细胞协议提供了详细的结果比较.

结论:

  • 开发的随机模型有效模拟CAR T细胞治疗,捕捉患者的变异性和异质性.
  • 该模型对治愈和进展时间的预测为优化治疗方案提供了宝贵的见解.
  • 这种方法通过提供一个定量框架来评估CAR T细胞治疗的疗效来支持临床研究.